{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Bonanno LM"],"funding":["NIDA NIH HHS","NIAID NIH HHS"],"pagination":["9711-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3064484"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["82(23)"],"pubmed_abstract":["In this work, we evaluate for the first time the performance of a label-free porous silicon (PSi) immunosensor assay in a blind clinical study designed to screen authentic patient urine specimens for a broad range of opiates. The PSi opiate immunosensor achieved 96% concordance with liquid chromatography-mass spectrometry/tandem mass spectrometry (LC-MS/MS) results on samples that underwent standard opiate testing (n = 50). In addition, successful detection of a commonly abused opiate, oxycodone, resulted in 100% qualitative agreement between the PSi opiate sensor and LC-MS/MS. In contrast, a commercial broad opiate immunoassay technique (CEDIA) achieved 65% qualitative concordance with LC-MS/MS. Evaluation of important performance attributes including precision, accuracy, and recovery was completed on blank urine specimens spiked with test analytes. Variability of morphine detection as a model opiate target was <9% both within-run and between-day at and above the cutoff limit of 300 ng mL(-1). This study validates the analytical screening capability of label-free PSi opiate immunosensors in authentic patient samples and is the first semiquantitative demonstration of the technology's successful clinical use. These results motivate future development of label-free PSi technology to reduce complexity and cost of diagnostic testing particularly in a point-of-care setting."],"journal":["Analytical chemistry"],"pubmed_title":["Label-free porous silicon immunosensor for broad detection of opiates in a blind clinical study and results comparison to commercial analytical chemistry techniques."],"pmcid":["PMC3064484"],"funding_grant_id":["K25 AI060884","F31 DA025398-01A1","K25 AI060884-05","T32 DA007232-25","F31DA025398","5K25AI060884","F31 DA025398","T32DA007232","T32 DA007232"],"pubmed_authors":["Kwong TC","Bonanno LM","DeLouise LA"],"additional_accession":[]},"is_claimable":false,"name":"Label-free porous silicon immunosensor for broad detection of opiates in a blind clinical study and results comparison to commercial analytical chemistry techniques.","description":"In this work, we evaluate for the first time the performance of a label-free porous silicon (PSi) immunosensor assay in a blind clinical study designed to screen authentic patient urine specimens for a broad range of opiates. The PSi opiate immunosensor achieved 96% concordance with liquid chromatography-mass spectrometry/tandem mass spectrometry (LC-MS/MS) results on samples that underwent standard opiate testing (n = 50). In addition, successful detection of a commonly abused opiate, oxycodone, resulted in 100% qualitative agreement between the PSi opiate sensor and LC-MS/MS. In contrast, a commercial broad opiate immunoassay technique (CEDIA) achieved 65% qualitative concordance with LC-MS/MS. Evaluation of important performance attributes including precision, accuracy, and recovery was completed on blank urine specimens spiked with test analytes. Variability of morphine detection as a model opiate target was <9% both within-run and between-day at and above the cutoff limit of 300 ng mL(-1). This study validates the analytical screening capability of label-free PSi opiate immunosensors in authentic patient samples and is the first semiquantitative demonstration of the technology's successful clinical use. These results motivate future development of label-free PSi technology to reduce complexity and cost of diagnostic testing particularly in a point-of-care setting.","dates":{"release":"2010-01-01T00:00:00Z","publication":"2010 Dec","modification":"2020-10-31T08:20:35Z","creation":"2019-03-27T00:40:03Z"},"accession":"S-EPMC3064484","cross_references":{"pubmed":["21062030"],"doi":["10.1021/ac101804s"]}}